Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques - Wikidata - wikimedia - TriplyDB

Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques

Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques

http://www.wikidata.org/entity/Q35180144

about

Humanin, a cytoprotective peptide, is expressed in carotid atherosclerotic [corrected] plaques in humans Dysfunctional High-Density Lipoprotein: An Innovative Target for Proteomics and Lipidomics Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention Crystal Structure of Human Plasma Platelet-activating Factor Acetylhydrolase: STRUCTURAL IMPLICATION TO LIPOPROTEIN BINDING AND CATALYSIS Effect of darapladib treatment on endarterectomy carotid plaque lipoprotein-associated phospholipase A2 activity: a randomized, controlled trial Lp-PLA2 Inhibition-The Atherosclerosis Panacea?Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies.Pulse wave velocity and carotid atherosclerosis in white and Latino patients with hypertension Lp-PLA2 Inhibitors for the Reduction of Cardiovascular Events Lyso-phosphatidylcholine induces osteogenic gene expression and phenotype in vascular smooth muscle cells.Inhibition of lipoprotein-associated phospholipase A2 ameliorates inflammation and decreases atherosclerotic plaque formation in ApoE-deficient mice.Genome-wide association study identifies novel loci associated with circulating phospho- and sphingolipid concentrations.Lipoprotein-associated phospholipase A₂ is related to plaque stability and is a potential biomarker for acute coronary syndrome.Plasma lipoprotein-associated phospholipase A2 in patients with metabolic syndrome and carotid atherosclerosis.Lipoprotein associated phospholipase A(2): role in atherosclerosis and utility as a biomarker for cardiovascular risk.Metabolomics predicts stroke recurrence after transient ischemic attack.Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2 Association of Lp-PLA2-A and early recurrence of vascular events after TIA and minor stroke.Effects of omega-3 fatty acids on arterial stiffness in patients with hypertension: a randomized pilot study Osteocalcin positive CD133+/CD34-/KDR+ progenitor cells as an independent marker for unstable atherosclerosis.Longitudinal Changes in Vascular Risk Markers and Mortality Rates among a Latino Population with Hypertension.Correlation between plasma lipoprotein-associated phospholipase A2 and peripheral arterial disease.Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: therapeutic strategies.Multimarker approach in discriminating patients with symptomatic and asymptomatic atherosclerotic carotid artery stenosis Use of Plasma Metabolomics to Identify Diagnostic Biomarkers for Early Stage Epithelial Ovarian Cancer.Lipoprotein(a): a promising marker for residual cardiovascular risk assessment.Relationship of lipoprotein-associated phospholipase A2 and oxidized low density lipoprotein in carotid atherosclerosis.The elevation of apoB in hypercholesterolemic patients is primarily attributed to the relative increase of apoB/Lp-PLA₂.Expression of lipoprotein-associated phospholipase A(2) in carotid artery plaques predicts long-term cardiac outcome.Lipoprotein-associated phospholipase A2 is associated with atherosclerotic stroke risk: the Northern Manhattan Study.The Early Effect of Carotid Artery Stenting on Antioxidant Capacity and Oxidative Stress in Patients with Carotid Artery Stenosis Clinical application of blood biomarkers in cerebrovascular disease.Lipoprotein-associated phospholipase A2: role in atherosclerosis and utility as a cardiovascular biomarker.The role of lipoprotein-associated phospholipase a₂ as a marker and potential therapeutic target in atherosclerosis.The incremental value of lipids and inflammatory biomarkers in determining residual cardiovascular risk.Effects of dietary factors on lipoprotein-associated phospholipase A(2) (Lp-PLA (2)).Lipoprotein-associated phospholipase A2 (Lp-PLA2): a review of its role and significance as a cardiovascular biomarker.Cardiovascular Disease Risk Assessment: Review of Established and Newer Modalities.Association between Lp-PLA2 and coronary heart disease in Chinese patients.Simvastatin reduces expression and activity of lipoprotein-associated phospholipase A(2) in the aorta of hypercholesterolaemic atherosclerotic rabbits.

P2860

Q21134790-9FBB7894-0E21-47C1-B19E-29B1A5FE2F5A Q26774903-BD90516E-EC3C-4316-BC55-2F0FF02A5285 Q26997377-CE46A5D5-8F65-4E14-8864-75E4D42845B4 Q27652078-56DC649F-1FB6-48F1-BF9C-C534140AE413 Q28539991-0BB47189-F8FB-4C3C-98B6-7783BCBAF9EA Q33664272-ED6ABED5-B11F-4577-AA42-05B5F8EFB136 Q33829154-CFBF0249-23DE-4562-B959-A0DA6B8EF84D Q33868239-757E7FA9-915C-4FD9-9B0A-2D830415150A Q33936097-9605CB1F-84B1-4852-8876-FE588E0AEF3E Q33987854-D0D4EDC9-7B56-4B4C-BE25-26AF269999A9 Q34016317-B88AC71E-2968-4C9A-8A7F-C44AA1605198 Q34167926-120A7AF7-8F62-4E5D-8888-3941CD9BA95F Q34384281-6B3C2A81-5A90-4D6F-987C-611A4AF8A1E2 Q34541071-65EBFEB4-80F9-4E11-9CE2-4F49D60D1CDF Q34890672-6FE5B009-6026-4255-8B14-3F4A958513B1 Q35106564-16B2C260-DFB2-48F9-9274-94D38B36ECD3 Q36145180-B839A045-A989-45F1-B3E7-9ED2A50F790A Q36272238-4ECC66DF-DA2B-4D70-8721-853E533AE736 Q36344009-6C87ECCA-A2E8-47FC-9C41-1CA1DE4A3539 Q36438740-A2D47C68-4822-481B-B003-7C096BEC4F1F Q36837228-F9CA5048-343C-473D-B996-B5B98EC29973 Q36900840-1CC03FE9-FC16-4829-B700-4DFE1EA38757 Q36925788-AA103B30-054C-4617-9205-32C6B9CFCF0B Q37043341-6A0F461D-83BD-40D2-B3BF-B6ECC5C1FF15 Q37068001-273080E1-9D54-4506-91CD-C561EBE638AC Q37285933-5BDFD76F-0FC6-4E59-93DC-12D2C9043E10 Q37299885-12CB2D64-7E80-4078-988B-EACA3AD3FDF4 Q37305388-C7435F9A-F1C7-4691-A683-6DE122070887 Q37449321-61EBB55F-136F-47B6-AC12-158BC05368DC Q37458449-F615288F-C092-4121-B8B1-5C87CC3F07C7 Q37533434-E945B076-816C-40A7-995F-52F0FC8604F7 Q37688066-A30446DC-945E-4C2E-910D-A10A67D3DA74 Q37707415-D6AD2A6A-13B3-40AA-ADF5-6B924ADB912D Q37826117-6B912985-1941-4081-B2F1-71C4EB6AA54C Q37902963-D05C96F4-1A0C-4AE3-9D8C-C854E6FA87A3 Q37922624-387FB30A-B480-413A-949F-3CF31D20BD43 Q37991749-B757949F-BDDF-4705-8B07-3395CB1446CC Q38608589-B8D29A7F-DF26-4B77-854D-A99F26B0C828 Q38949810-4580B458-8D94-419E-9BD2-8BA6A54BA311 Q43275289-404DECCB-7D4C-430C-8964-8AC509CF68D8

P2860

Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques

http://www.wikidata.org/entity/Q35180144

description

2008 nî lūn-bûn

@nan

2008 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի մարտին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Enhanced expression of Lp-PLA2 ...... arotid atherosclerotic plaques

@ast

Enhanced expression of Lp-PLA2 ...... arotid atherosclerotic plaques

@en

type

label

Enhanced expression of Lp-PLA2 ...... arotid atherosclerotic plaques

@ast

Enhanced expression of Lp-PLA2 ...... arotid atherosclerotic plaques

@en

prefLabel

Enhanced expression of Lp-PLA2 ...... arotid atherosclerotic plaques

@ast

Enhanced expression of Lp-PLA2 ...... arotid atherosclerotic plaques

@en

P1433

Q35180144-0B8D3BB0-8C7A-4898-9571-7CA8DC0E8E24

P1476

Q35180144-EFC233F2-72DC-4BE7-8CA3-95FC05687AD7

P2093

Q35180144-2BCDFBE7-343C-48C1-8FD4-739D6689C3EB

Q35180144-4160FBD7-C9CC-459D-96CC-2F38D245B8D6

Q35180144-6F0FA907-B461-4BFF-AF19-AF5877D6D106

Q35180144-C58DB38A-2B08-44B5-B46A-91CA46C961BF

Q35180144-CCC37303-5609-4345-A69A-5C1F065D3E65

Q35180144-F8BB9B45-8F35-4EDE-A427-10A3CBCC4B46

P2860

Q35180144-0995FBB8-865C-43FF-846C-C173BB60FAE4

Q35180144-09C3AD74-0274-431C-ABE4-092D37A609F7

Q35180144-192D42FC-A1D0-4847-9044-678390EAEF87

Q35180144-1AD5D8B3-A84D-4389-8366-2B83BC63891D

Q35180144-1F2F7CDC-E9AD-4F5F-8BB7-24CBD544F1F9

Q35180144-22043C7F-3745-4C22-A9D0-75B782ED7DC3

Q35180144-4C1F6502-C084-4118-B19F-572607963A7B

Q35180144-4FA04FDE-3CCB-4281-B5B3-AEAE6D19825B

Q35180144-5D60E0F6-1311-415B-9926-F9D5C4A4F5E4

Q35180144-673576F4-83AF-4FBC-87C6-E2EF697DFB29

P304

Q35180144-413684C5-0FA4-40DD-9538-9823296C403E

P31

Q35180144-AA5F0001-F736-48A8-B9AB-2A94F7132F6C

P356

Q35180144-E368E110-BB63-4F30-B8E7-8F6BD917111F

P407

Q35180144-6E02214D-440E-4541-921E-E1075ABBEC70

P433

Q35180144-BEE1890B-A4EC-4295-BABB-34A89EC1D89A

P478

Q35180144-957E4480-85D1-46EE-B997-0DE9B8DF9BF3

P50

Q35180144-67128C55-76A5-4E9B-8C4E-4C5F9348194B

Q35180144-B643E8A5-E4FB-4317-A7D5-AD1910194890

P577

Q35180144-0267EF20-BBF2-4B18-9470-6C002BCB610C

P698

Q35180144-53786A9A-BE1A-435B-894E-92EA628D7275

P921

Q35180144-372905F0-6CA7-4E76-AC97-F80EB8B5D7D7

P932

Q35180144-2E2564A6-BC3F-4A2D-B7FE-F8D75EB2BC2B

P356

STROKEAHA.107.503193

P1433

P1476

Enhanced expression of Lp-PLA2 ...... arotid atherosclerotic plaques

@en

P2093

Dallit Mannheim

http://www.w3.org/2001/XMLSchema#string

Daniele Versari

http://www.w3.org/2001/XMLSchema#string

Fredric B Meyer

http://www.w3.org/2001/XMLSchema#string

Joerg Herrmann

http://www.w3.org/2001/XMLSchema#string

Joseph P McConnell

http://www.w3.org/2001/XMLSchema#string

Mario Gössl

http://www.w3.org/2001/XMLSchema#string

P2860

Purification, properties, sequencing, and cloning of a lipoprotein-associated, serine-dependent phospholipase involved in the oxidative modification of low-density lipoproteins

Concurrent treatment with renin-angiotensin system blockers and acetylsalicylic acid reduces nuclear factor kappaB activation and C-reactive protein expression in human carotid artery plaques

Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study

Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization.

Lysophosphatidylcholine increases the secretion of matrix metalloproteinase 2 through the activation of NADH/NADPH oxidase in cultured aortic endothelial cells.

Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis

The symptomatic carotid plaque.

Early risk of stroke after a transient ischemic attack in patients with internal carotid artery disease.

Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress.

Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern G

P304

1448-1455

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/STROKEAHA.107.503193

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

39

http://www.w3.org/2001/XMLSchema#string

P50

Lilach O. Lerman

P577

2008-03-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18356547

http://www.w3.org/2001/XMLSchema#string

P921

atherosclerosis

P932

4360896

http://www.w3.org/2001/XMLSchema#string